Personalis logo
Personalis
PSNL | NASDAQ
Chart Builder DCF Calculator
$14.80
-$0.91 (-5.79%)
At close: Nov 16, 2026, 4:00 PM ET
$14.59
-$0.21 (-1.42%)
After-hours: Nov 16, 2026, 7:30 PM ET

Personalis Company Profile

Company profile explained

Company Profile

Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis; NeXT Personal, a specific liquid biopsy designed for individual patient tumor tracking; the NeXT Dx Test, a genomic cancer profiling tool that identifies composite biomarkers for treatment guidance; and the sophisticated NeXT SHERPA and NeXT NEOPS for predicting neoantigens. Additionally, Personalis offers the ACE platform, utilized for diverse clinical and therapeutic applications like neoantigen prediction, biomarker identification, and the selection of new drug targets. Their clientele includes biopharmaceutical companies, academic institutions, non-profit organizations, and government entities. The company has established significant partnerships with organizations such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center. Personalis, Inc. was founded in 2011 and is based in Menlo Park, California.

Key Executives

Name Position
Christopher Hall CEO & Director
Aaron L. Tachibana Chief Financial Officer & Chief Operating Officer
Ashish Kheterpal Senior Vice President & Chief Information Officer
Stephen Moore Senior Vice President, Chief Legal Officer & Corporate Secretary
Christian Haudenschild Senior Vice President of Genomic Science
Euan A. Ashley DPHIL FRCP Co-Founder and Member of Clinical & Scientific Advisory Board
Michael Snyder Co-Founder and Member of Clinical & Scientific Advisory Board
Richard Chen President & Chief Medical Officer
Russ Altman Co-Founder and Member of Clinical & Scientific Advisory Board
Stephane Mouradian Senior Vice President of Business Development

Latest SEC Filings

Date Type Title
Oct 30, 2026 425 Filing
Oct 21, 2026 DEFM14A Filing
Oct 21, 2026 425 Filing
Oct 20, 2026 425 Filing
Oct 20, 2026 SC 13E3/A [Amend] Filing
Oct 06, 2026 425 Filing
Oct 06, 2026 8-K Current Report
Oct 02, 2026 SC 13E3/A [Amend] Filing
Oct 02, 2026 CT ORDER Filing
Sep 22, 2026 4 Filing
View All SEC Filings ➞
Personalis
Personalis logo
Country United States
IPO Date Jun 20, 2019
Industry Medical - Diagnostics & Research
Sector Healthcare
Employees 260
CEO Christopher Hall

Contact Details

6600 Dumbarton Circle Fremont, California 94555 United States

Stock Details

Ticker Symbol PSNL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001527753
CUSIP Number 71535D106
ISIN Number US71535D1063
SIC Code 8071

Recent News

More News ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.